330 related articles for article (PubMed ID: 27301849)
1. Using the Comprehensive Complication Index to Assess the Impact of Neoadjuvant Chemoradiotherapy on Complication Severity After Esophagectomy for Cancer.
Nederlof N; Slaman AE; van Hagen P; van der Gaast A; Slankamenac K; Gisbertz SS; van Lanschot JJ; Wijnhoven BP; van Berge Henegouwen MI;
Ann Surg Oncol; 2016 Nov; 23(12):3964-3971. PubMed ID: 27301849
[TBL] [Abstract][Full Text] [Related]
2. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M
Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemoradiotherapy may increase the risk of severe anastomotic complications after esophagectomy with cervical anastomosis.
Klevebro F; Friesland S; Hedman M; Tsai JA; Lindblad M; Rouvelas I; Lundell L; Nilsson M
Langenbecks Arch Surg; 2016 May; 401(3):323-31. PubMed ID: 27020672
[TBL] [Abstract][Full Text] [Related]
4. Impact of Neoadjuvant Chemoradiation on Short-Term Outcomes for Esophageal Squamous Cell Carcinoma Patients: A Meta-analysis.
Sathornviriyapong S; Matsuda A; Miyashita M; Matsumoto S; Sakurazawa N; Kawano Y; Yamada M; Uchida E
Ann Surg Oncol; 2016 Oct; 23(11):3632-3640. PubMed ID: 27278203
[TBL] [Abstract][Full Text] [Related]
5. Surgical Morbidity and Mortality From the Multicenter Randomized Controlled NeoRes II Trial: Standard Versus Prolonged Time to Surgery After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.
Nilsson K; Klevebro F; Rouvelas I; Lindblad M; Szabo E; Halldestam I; Smedh U; Wallner B; Johansson J; Johnsen G; Aahlin EK; Johannessen HO; Hjortland GO; Bartella I; Schröder W; Bruns C; Nilsson M
Ann Surg; 2020 Nov; 272(5):684-689. PubMed ID: 32833767
[TBL] [Abstract][Full Text] [Related]
6. Impact of neoadjuvant chemotherapy and chemoradiotherapy on postoperative cardiopulmonary complications in patients with esophageal cancer.
Zhang Z; Zhang H
Dis Esophagus; 2017 Apr; 30(4):1-7. PubMed ID: 28375486
[TBL] [Abstract][Full Text] [Related]
7. Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial.
Noordman BJ; Verdam MGE; Lagarde SM; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch OR; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Spillenaar Bilgen EJ; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A; Sprangers MAG; van Lanschot JJB
J Clin Oncol; 2018 Jan; 36(3):268-275. PubMed ID: 29161204
[TBL] [Abstract][Full Text] [Related]
8. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
[TBL] [Abstract][Full Text] [Related]
9. Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer.
Sihag S; Ku GY; Tan KS; Nussenzweig S; Wu A; Janjigian YY; Jones DR; Molena D
J Thorac Cardiovasc Surg; 2021 Mar; 161(3):836-843.e1. PubMed ID: 33485662
[TBL] [Abstract][Full Text] [Related]
10. Impact of neoadjuvant chemoradiotherapy on postoperative outcomes after esophageal cancer resection: results of a European multicenter study.
Gronnier C; Tréchot B; Duhamel A; Mabrut JY; Bail JP; Carrere N; Lefevre JH; Brigand C; Vaillant JC; Adham M; Msika S; Demartines N; El Nakadi I; Piessen G; Meunier B; Collet D; Mariette C; ; Luc G; Cabau M; Jougon J; Badic B; Lozach P; Cappeliez S; Lebreton G; Alves A; Flamein R; Pezet D; Pipitone F; Iuga BS; Contival N; Pappalardo E; Mantziari S; Hec F; Vanderbeken M; Tessier W; Briez N; Fredon F; Gainant A; Mathonnet M; Bigourdan JM; Mezoughi S; Ducerf C; Baulieux J; Pasquer A; Baraket O; Poncet G; Vaudoyer D; Enfer J; Villeneuve L; Glehen O; Coste T; Fabre JM; Marchal F; Frisoni R; Ayav A; Brunaud L; Bresler L; Cohen C; Aze O; Venissac N; Pop D; Mouroux J; Donici I; Prudhomme M; Felli E; Lisunfui S; Seman M; Petit GG; Karoui M; Tresallet C; Ménégaux F; Hannoun L; Malgras B; Lantuas D; Pautrat K; Pocard M; Valleur P
Ann Surg; 2014 Nov; 260(5):764-70; discussion 770-1. PubMed ID: 25379847
[TBL] [Abstract][Full Text] [Related]
11. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.
Lin G; Han SY; Xu YP; Mao WM
Dis Esophagus; 2016 Nov; 29(8):1107-1114. PubMed ID: 26542065
[TBL] [Abstract][Full Text] [Related]
12. Effects of neoadjuvant chemoradiotherapy on postoperative morbidity and mortality associated with esophageal cancer.
Hamai Y; Hihara J; Taomoto J; Yamakita I; Ibuki Y; Okada M
Dis Esophagus; 2015; 28(4):358-64. PubMed ID: 24612033
[TBL] [Abstract][Full Text] [Related]
13. Active surveillance in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal or junctional cancer.
Noordman BJ; Wijnhoven BPL; Lagarde SM; Biermann K; van der Gaast A; Spaander MCW; Valkema R; van Lanschot JJB
Dis Esophagus; 2017 Dec; 30(12):1-8. PubMed ID: 28881890
[TBL] [Abstract][Full Text] [Related]
14. Radiation to the Gastric Fundus Increases the Risk of Anastomotic Leakage After Esophagectomy.
Goense L; van Rossum PSN; Ruurda JP; van Vulpen M; Mook S; Meijer GJ; van Hillegersberg R
Ann Thorac Surg; 2016 Dec; 102(6):1798-1804. PubMed ID: 27765168
[TBL] [Abstract][Full Text] [Related]
15. Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer.
Shapiro J; van Hagen P; Lingsma HF; Wijnhoven BP; Biermann K; ten Kate FJ; Steyerberg EW; van der Gaast A; van Lanschot JJ;
Ann Surg; 2014 Nov; 260(5):807-13; discussion 813-4. PubMed ID: 25379852
[TBL] [Abstract][Full Text] [Related]
16. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial.
Noordman BJ; Verdam MGE; Lagarde SM; Shapiro J; Hulshof MCCM; van Berge Henegouwen MI; Wijnhoven BPL; Nieuwenhuijzen GAP; Bonenkamp JJ; Cuesta MA; Plukker JTM; Spillenaar Bilgen EJ; Steyerberg EW; van der Gaast A; Sprangers MAG; van Lanschot JJB;
Ann Oncol; 2018 Feb; 29(2):445-451. PubMed ID: 29126244
[TBL] [Abstract][Full Text] [Related]
17. 15-Year Experience with Multimodality Therapy Including Esophagectomy for Elderly Patients with Locoregional Esophageal Cancer.
Sawyer WP; Luo X; Welch AM; Bolton NM; Brown R; Bolton JS
J Am Coll Surg; 2021 Apr; 232(4):580-588. PubMed ID: 33549634
[TBL] [Abstract][Full Text] [Related]
18. Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? A meta-analysis.
Qin Q; Xu H; Liu J; Zhang C; Xu L; Di X; Zhang X; Sun X
Int J Surg; 2018 Nov; 59():11-18. PubMed ID: 30261331
[TBL] [Abstract][Full Text] [Related]
19. Prolonged interval between neoadjuvant chemoradiotherapy and esophagectomy does not benefit the outcome in esophageal cancer: a systematic review and meta-analysis.
Tie H; He F; Shen J; Zhang B; Ye M; Chen B; Wu Q
Dis Esophagus; 2018 Jan; 31(1):1-9. PubMed ID: 29087451
[TBL] [Abstract][Full Text] [Related]
20. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study.
Goense L; Visser E; Haj Mohammad N; Mook S; Verhoeven RHA; Meijer GJ; van Rossum PSN; Ruurda JP; van Hillegersberg R
Eur J Surg Oncol; 2018 May; 44(5):620-625. PubMed ID: 29478739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
